Pfizer to Buy King Pharmaceuticals for $3.6 Billion

Oct. 12, 2010
Pfizer said deal will help company in 'offering both currently marketed opioid and non-opioid products, as well as a pipeline spanning stages of clinical development.'

In a bid to boost its position in the pain-relief market, Pfizer, the world's largest drug maker, said on Oct. 12 that it will buy King Pharmaceuticals for $3.6 billion.

Pfizer said it had struck a "definitive merger agreement" with King at $14.25 per share, representing about a 40% premium to King's closing price on Oct. 11.

The acquisition "will advance Pfizer's strategic objectives by strengthening its position within the rapidly growing pain-relief market," the companies said.

"This strategic combination will allow Pfizer to leverage its existing commercial capabilities and expertise to create one of the leading broad portfolios for pain relief and management in the biopharmaceutical industry, offering both currently marketed opioid and non-opioid products, as well as a pipeline spanning stages of clinical development," said the New York City-based Pfizer and King, headquartered in Bristol, Tennessee.

Jeffrey Kindler, Pfizer CEO, said the tie-up in that area of "unmet medical need" was highly complementary.

The deal "will allow us to offer a fuller spectrum of treatments for patients across the globe who are in need of pain relief and management," he said.

Copyright Agence France-Presse, 2010

Popular Sponsored Recommendations

The Benefits of Continuous Thermal Monitoring

Oct. 17, 2023
Read this eBook to learn more about collecting and using data intelligently to improve performance.

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

Process Mining For Dummies

Nov. 19, 2023
Here it is. Everything you need to know about process mining in a single book, written in the easy-to-understand, hard-to-forget style that ‘For Dummies’ manages so effortlessly...

Are You Positioned To Tackle Supply Chain Risk?

Sept. 20, 2023
Supply chain disruption is here to stay, but you can keep ahead of potential issues — and identify new opportunities — by regularly assessing your suppliers. Download our supplier...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!